Genetic Evidence Suggests GLP-1 Drugs May Protect Against Diabetic and IgA Kidney Disease Through Anti-Inflammatory Pathways | Research

The takeaway

Mendelian randomization analysis found genetic evidence that GLP-1 receptor agonists reduce the risk of diabetic nephropathy by 28% and IgA nephropathy by 42%, with about a third of the IgA nephropathy effect mediated through an inflammatory protein.

42% lower IgA nephropathy risk
Genetically proxied GLP-1 receptor agonist exposure was associated with a 42% reduced risk of IgA nephropathy (OR 0.58), with about one-third of this effect mediated through the inflammatory protein SLAMF1.

What the researchers found

Genetically proxied GLP-1 receptor agonist exposure was significantly associated with decreased risk of two kidney diseases:

- Diabetic nephropathy: OR = 0.72 (95% CI: 0.54-0.97, p = 0.031) — a 28% risk reduction

- IgA nephropathy: OR = 0.58 (95% CI: 0.36-0.94, p = 0.027) — a 42% risk reduction

Two-stage network Mendelian randomization revealed that 34.27% (95% CI: 1.47-67.03%, p = 0.041) of the GLP-1 receptor agonist effect on IgA nephropathy was mediated through SLAMF1 (signaling lymphocytic activation molecule family member 1), an inflammatory protein. No significant associations were found with membranous nephropathy, nephrotic syndrome, chronic kidney disease, acute or chronic glomerulonephritis, or kidney stones.

Why it matters

This study provides genetic evidence that GLP-1 receptor agonists — already widely used for diabetes and obesity — may have protective effects on kidney diseases beyond their metabolic benefits. The finding for IgA nephropathy is particularly significant because this is a common autoimmune kidney disease with limited treatment options. Identifying SLAMF1 as a mediator suggests a specific anti-inflammatory mechanism that could guide future research and potentially expand the therapeutic use of GLP-1 drugs.

How the study worked

The researchers used two-sample Mendelian randomization (MR), a genetic epidemiology method that uses naturally occurring genetic variants (cis-eQTLs for GLP1R) as proxies for drug exposure to estimate causal effects while minimizing confounding. They tested associations between genetically proxied GLP-1 receptor activation and eight kidney diseases across discovery and validation cohorts. Type 2 diabetes and BMI served as positive controls. Two-stage network MR was used to identify inflammatory protein mediators of the observed effects.

What this study cannot tell us

Mendelian randomization uses genetic proxies rather than actual drug exposure, so results may not perfectly translate to clinical practice. The effect sizes and confidence intervals are wide, particularly for the mediation analysis. The study primarily used European-ancestry genetic data, limiting generalizability. MR assumes the genetic variants only affect kidney disease through GLP-1 receptor activation (no horizontal pleiotropy), which may not hold for all variants. Clinical trials would be needed to confirm these genetically predicted effects.

How to read the evidence

Mendelian randomization provides stronger causal inference than observational studies by using genetic variants as natural experiments, but it is not as definitive as randomized controlled trials. The study includes both discovery and validation cohorts and identifies a plausible inflammatory mediator, placing it at a moderate-high evidence level for genetic epidemiology.

When this study was published

Published in 2025, this is a very recent study reflecting the latest genetic evidence on GLP-1 receptor agonist effects beyond metabolic conditions.

The bigger picture

GLP-1 receptor agonists are increasingly recognized for benefits extending far beyond blood sugar control — including heart protection, weight loss, and now potentially kidney disease prevention. This study adds to evidence that these peptide drugs have broad anti-inflammatory properties that could make them useful across multiple organ systems. The identification of SLAMF1 as a specific inflammatory mediator connects GLP-1 biology to immune regulation, opening new research directions.

Questions still open

Should clinical trials of GLP-1 receptor agonists now be designed specifically for IgA nephropathy patients?
Could targeting SLAMF1 directly provide additional kidney protection beyond what GLP-1 drugs offer?
Do these kidney-protective effects differ between different GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide)?

Common questions

What is Mendelian randomization and why is it used here?

Mendelian randomization is a research method that uses naturally occurring genetic variations as stand-ins for drug exposure. Because genes are randomly assigned at conception, this approach mimics a natural clinical trial and can suggest causal relationships. Here, researchers used genetic variants that increase GLP-1 receptor activity to estimate what would happen if people were treated with GLP-1 drugs long-term.

Could GLP-1 medications like semaglutide be used to treat IgA nephropathy?

This study provides genetic evidence suggesting a protective effect, but GLP-1 drugs are not currently approved for IgA nephropathy. Clinical trials specifically testing these medications in IgA nephropathy patients would be needed before they could be recommended for this purpose. However, the findings provide a strong rationale for conducting such trials.

Read the original research

Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.

Renal failure, 47(1), 2478488

View on PubMed ↗Publisher’s paper ↗

Citation

Yao, Yu-Xuan; Tang, Chen; Si, Feng-Lei; Lv, Ji-Cheng; Shi, Su-Fang; Zhou, Xu-Jie; Liu, Li-Jun; Zhang, Hong. (2025). Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization.. Renal failure, 47(1), 2478488. https://doi.org/10.1080/0886022X.2025.2478488